Pictet Asset Management (UK)’s Puma Biotechnology PBYI Stock Holding History

Pictet Asset Management (UK)’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-118,800	Closed	-$4.61M	–	1041
2019 Q1	$4.61M	Buy	118,800 +41,300	+53%	+$1.26M	0.01%	720
2018 Q4	$1.58M	Sell	77,500 -341,986	-82%	-$10.3M	﹤0.01%	856
2018 Q3	$19.2M	Buy	419,486 +93,865	+29%	+$4.53M	0.04%	425
2018 Q2	$19.3M	Buy	325,621 +37,141	+13%	+$2.15M	0.05%	403
2018 Q1	$19.6M	Buy	+288,480	New	+$21.6M	0.05%	384
2015 Q4	–	Sell	-10,470	Closed	-$789K	–	862
2015 Q3	$789K	Buy	10,470 +220	+2%	+$20.8K	﹤0.01%	803
2015 Q2	$929K	Buy	+10,250	New	+$1.86M	﹤0.01%	806

Other funds holding PBYI

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Pictet Asset Management (UK)'s PBYI Position: Q2 2019 in Review

Pictet Asset Management (UK) sold out of Puma Biotechnology (PBYI) in Q2 2019, closing a stake of 118,800 shares — an estimated $4.61M sold.

Pictet Asset Management (UK) first reported a position in PBYI in Q2 2015 and held it in 7 quarters. The position peaked at $19.6M in Q1 2018. 139 funds tracked by Wall St. Rank hold PBYI as of Q2 2019.

Pictet Asset Management (UK) reported no remaining Puma Biotechnology position as of Q2 2019 after selling out during the quarter.
Pictet Asset Management (UK) sold 118,800 Puma Biotechnology shares in Q2 2019, an estimated $4.61M.
Pictet Asset Management (UK) first reported a position in Puma Biotechnology in Q2 2015 and held it in 7 quarters.
Pictet Asset Management (UK)'s Puma Biotechnology position peaked at $19.6M in Q1 2018.
139 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2019.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2019, filed 13 Aug 2019.